MedTrace Logo

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

NCT07645651 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-08-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.

Conditions

  • Resectable Pancreatic Ductal Adenocarcinoma
  • Borderline Resectable Pancreatic Ductal Adenocarcinoma
  • Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

Samuraciclib

Given PO

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Endoscopic Ultrasound Biopsy

Undergo EUS/FNB

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Sponsors & Collaborators

  • Lopker Family Foundation

    collaborator UNKNOWN

  • Carrick Therapeutics Limited

    collaborator INDUSTRY

  • The V Foundation for Cancer Research

    collaborator OTHER

  • University of Washington

    lead OTHER

Principal Investigators

  • Rachael Safyan, MD · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-15
Primary Completion
2027-07-14
Completion
2027-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645651 on ClinicalTrials.gov